MIT, E8 Refer IP Suit against Affy, Navigenics to Federal Appeals Court after District Court Dismissal | GenomeWeb

A four-year-old patent-infringement suit brought by the Massachusetts Institute of Technology and E8 Pharmaceuticals against Affymetrix and its customer Navigenics is certain to carry on following a new legal move.

On Sept. 26, five days after a judge in the US District Court for the District of Massachusetts dismissed MIT and E8's claims in the case, as well as Affy and Navigenics' counterclaims, MIT and E8 appealed the decision to the US Court of Appeals for the Federal Circuit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.